Cardinal Health (CAH) has outperformed the stock market. Its Global Launch of Kendall SCD SmartFlow System could potentially alter its bullish outlook. Strong Q1 earnings are anticipated, driven by pharmaceutical and specialty business units. CAH's Relative Strength Rating saw an increase. The firm aims to expand the pharmaceutical distribution network with a new facility in Indianapolis.
Stock price dipped, despite market gains. CAH also continues expanding its U.S. distribution network. CAH shareholders saw a 30% CAGR over the last five years, making it a desirable long-tail investment. Nevertheless, CAH stock value descended drastically, impacting investors negatively. Despite missing Q2 revenue estimates, the company saw a potential 15.86% upside in the healthcare sector.
CAH also reported its fourth quarter and fiscal year 2025 results while raising fiscal year 2026 guidance. The company acquired Solaris Health for $1.9B. The addition of Solaris Health, a leading urology MSO, to The Specialty Alliance was announced. With 89% institutional ownership, CAH is a favorite amongst large investors.
CAH extended its receivables purchase agreement to 2028. However, CAH's revenue is expected to dip in 2025 amidst OptumRx contract loss. Its insiders are also disposing of stock, signaling possible bearish effects.
Cardinal Health CAH News Analytics from Sun, 26 Jan 2025 08:00:00 GMT to Fri, 24 Oct 2025 22:00:02 GMT -
Rating +3
- Innovation +2
- Information +5
- Rumor -2
